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Treatment of tuberculosis has many side effects. Thrombocytopenia is a serious side effect of such treatment and
occurs mostly due to rifampicin (RIF). There are very few reported cases of thrombocytopenia due to isoniazid
(INH). An 18-year-old female patient was diagnosed with smear-positive pulmonary tuberculosis. A four-drug
regimen [INH, RIF, ethambutol (EMB), and pyrazinamide (PZA)] was given. After the development of
thrombocytopenia, the drug treatment was stopped, and a thrombocyte suspension was given until a normal
thrombocyte count was obtained. After several start-stop trials, first INH and then RIF were identified as the possible
causes of thrombocytopenia and were removed from the regimen. The patient was treated with EMB,
streptomycin, PZA, and moxifloxacin with no further development of thrombocytopenia. The current case shows
that antituberculosis drugs other than RIF and PZA may be responsible for the development of thrombocytopenia.
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Tuberculosis is a chronic granulomatous infection that has
caused mortality and morbidity for centuries. Treatment of
this disease is problematic because of its long duration and
compliance problems. One of the most important factors
causing low compliance is the adverse effects of the drugs.
Some of them are self-limiting, but some require treatment
cessation. Common adverse effects are hepatotoxicity,
hypersensitivity reactions, loss of vision, loss of hearing,
flu-like syndrome, hemolytic anemia, acute renal failure,
shock, neuropathy, arthralgia, and thrombocytopenia [1].
Although rare, severe thrombocytopenia may be life-
threatening. Here we describe the case of a patient affected
with thrombocytopenia caused by isoniazid (INH) and ri-
fampicin (RIF).Case presentation
An 18-year-old female with no known disease history was
admitted to another center with complaints of coughing
with sputum and weight loss. Chest x-ray and microscopic
examination of the sputum enabled a diagnosis of smear-
positive pulmonary tuberculosis. A four-drug regimen* Correspondence: fyakar@yahoo.com
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reproduction in any medium, provided the or(INH, 300 mg/day; RIF, 450 mg/day; ethambutol [EMB],
1,250 mg/day; and pyrazinamide [PZA], 1,500 mg/day)
was started according to her weight of 50 kg. While nor-
mal at the start of therapy (300,000/mm3), her thrombo-
cyte count began to decrease during the second day of
treatment (18,000/mm3). The therapy was stopped, and
after transfusions of fresh frozen plasma and a thrombo-
cyte suspension, her thrombocyte count became normal.
Rifampicin was assumed to be the causative factor of
thrombocytopenia, and therapy was restarted with INH,
PZA, and EMB. However, thrombocytopenia relapsed
during this regimen. The treatment was stopped and the
patient was referred to our hospital.
When the patient was admitted to our hospital, her main
complaint was coughing. No important previous history
was present. Physical examination findings were normal
with the exception of bilateral ecchymoses on her lower
extremities. Chest X-ray showed a cavity with peripheral
infiltration in the left upper zone. Laboratory findings
revealed; sedimentation rate: 46 mm/hr, CRP: 24 mg/lt,
WBC: 9,910/mm3, hemoglobin: 10 gr/dl, hematocrit: 31%,
and thrombocytes: 135,000/mm3. Other parameters were
noncontributory.
Because of the recurrent thrombocytopenia, we planned
to start a treatment with a single agent and add the others
one by one. The treatment was initiated in our hospital withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(30,000/mm3) on the third day, and the therapy was
stopped. As soon as the thrombocyte count became nor-
mal, we began a three-drug regimen according to the
patient’s weight: PZA, 1,500 mg/day; streptomycin (SM),
750 mg/day; and EMB, 1,250 mg/day. Because the thrombo-
cyte count was normal (225,000/mm3), INH was again
added to the regimen, but on the second day of INH initi-
ation, the thrombocyte count decreased to 10,000/mm3.
The INH was stopped and the patient underwent a consult-
ation in the Hematology Department. Then a thrombocyte
suspension and methylprednisolone (1 mg/kg/day) were
given. During the follow up, the thrombocyte count became
normal and the methylprednisolone therapy was stopped.
After re-initiation of the three-drug regimen (EMB, PZA,
and SM), RIF at 450 mg/day was added to the therapy as
the fourth drug. On the third day of RIF therapy, the
thrombocyte count decreased to 34,000/mm3 and RIF was
ceased.
Because of thrombocytopenia caused by both INH and
RIF, moxifloxacin at 400 mg/day was added to the treat-
ment regimen. Without INH and RIF, patient had no
further thrombocytopenia development during the
period of therapy. After the first month of the therapy,
her sputum smear was negative. There were no clinical
or laboratory abnormalities during follow up examina-
tions. After cessation of SM in the second month, the
antituberculosis treatment regimen was continued and
completed with three drugs (EMB, 1250 mg/day; PZA,
1500 mg/day; and moxifloxacin, 400 mg/day) without
any further complications.
Discussion and conclusions
Although there are reports of thrombocytopenia during
antituberculosis treatment, only few case reports of
INH-induced thrombocytopenia are reported [2-5], but
none where the hematologic disorder was at the same
time caused by INH and RIF. Our patient had recurrent
episodes of thrombocytopenia due to INH and RIF, ei-
ther together or separately.
A thrombocyte count of <150,000/mm3 is defined as
thrombocytopenia. However, 2.5% of the normal population
may have thrombocyte levels lower than this value [6]. The
main mechanisms of thrombocytopenia are decreased pro-
duction or increased destruction. Moreover, dilutional and
distributional mechanisms may contribute. Before diagnos-
ing thrombocytopenia, pseudothrombocytopenia, which
may occur due to ineffective anticoagulation in blood tubes,
thrombocyte clustering, or abciximab use, should be
excluded [7]. In our patient, pseudothrombocytopenia was
excluded with a peripheral blood smear examination.
Drug-induced thrombocytopenia is a frequent condi-
tion. George et al. collected case reports of drug-induced
thrombocytopenia and defined the standard criteria withwhom to explain the association between the drugs and
thrombocytopenia [8]. They defined four criteria: 1) the
suspected drug preceded thrombocytopenia and recovery
was complete and sustained after the drug withdrawal 2)
The suspected drug was the only drug used prior to the
onset, or other drugs were continued or reintroduced after
discontinuation of the suspected drug with a sustained
normal thrombocyte count. 3) Other etiologies of
thrombocytopenia were excluded. 4) Re-exposure to the
suspected drug resulted in recurrent thrombocytopenia. If
the suspected drug meets all criteria, then the level of evi-
dence is definite. If it meets the first three, it is probable; if
it meets only the first criterion, it is possible; and if the
first criterion is not met, then it is unlikely that it is the re-
sponsible agent. According to these criteria, both INH
and RIF in our patient met all of the criteria, and so the
level of evidence was definite.
Clinical findings usually appear when the thrombocyte
count decreases under a certain level. When thrombocytes
are lower than 20,000/mm3, spontaneous bleeding and ec-
chymoses may appear. There were ecchymoses on both
lower extremities of the present patient at admittance. RIF
is the most common cause of thrombocytopenia among
antituberculosis drugs. The drug binds noncovalently to
membrane glycoproteins to produce compound epitopes
or induce conformational changes for which antibodies
are specific [8]. In addition, RIF-dependent antibodies at-
tach to thrombocytes and cause increased destruction.
INH is a synthetic chemical and a pyridine derivative of
nicotinamide. The central nervous system, liver, and
hematological system are the main targets of INH toxicity.
It may induce acute or chronic disturbances of the
hematological system. Acutely it may cause leukocytosis,
and chronically it may determine anemia (hemolytic, side-
roblastic, aplastic, or megaloblastic), agranulocytosis, eo-
sinophilia, or thrombocytopenia; disseminated intravascular
coagulation and lymphadenopathy due to hypersensitivity
reactions have also been reported [9]. The exact mechanism
of INH-induced thrombocytopenia is not known.
Although INH-induced thrombocytopenia has been
defined previously, there are only four previous cases in
the literature, none of which was also RIF-induced. INH-
and RIF-induced thrombocytopenia in the present case
was diagnosed by the occurrence of thrombocytopenia
due to RIF in the treatment regimen without INH as well
as thrombocytopenia due to INH in the regimen without
RIF and exclusion of other potential diagnoses by a per-
ipheral blood smear. Nevertheless, thrombocytopenia is
rare but life-threatening. Early recognition and cessation
of treatment may prevent mortality and morbidity.
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